Table 1.
Common HIPEC regimens currently in use
| Center/Country | HIPEC drug (s) and doses | HIPEC duration | Concomitant intravenous | EPIC | Indication |
| (min) | chemotherapy | ||||
| Washington hospital center/ | Mitomycin C, 15 mg/m2 | 90 | 5-FU, 400 mg/m2 | 5-FU | Appendiceal, and |
| Washington, DC (USA) | Doxorubicin, 15 mg/m2 | LV, 20 mg/m2 | 4 d | colorectal carcinomatosis | |
| Washington hospital center/ | Cisplatin, 50 mg/m2 | 90 | 5-FU, 400 mg/m2 | Taxol | Gastric cancer, peritoneal |
| Washington, DC (USA) | Doxorubicin, 15 mg/m2 | LV, 20 mg/m2 | 4 d | mesothelioma, ovarian | |
| cancer | |||||
| Washington hospital center/ | Oxaliplatin, 130 mg/m2 | 60 | 5-FU, 400 mg/m2 | 5-FU | Appendiceal, and |
| Washington, DC (USA) | LV, 20 mg/m2 | 4 d | colorectal carcinomatosis | ||
| Washington hospital center/ | Melphalan, 50-70 mg/m2 | 60 | No | No | Carcinomatosis with |
| Washington, DC (USA) | incomplete cytoreduction | ||||
| Gustave roussy institute/ | Oxaliplatin, 460 mg/m2 | 30 | 5-FU, 400 mg/m2 | No | Colorectal carcinomatosis |
| Villejuif (France) | LV, 20 mg/m2 | ||||
| National cancer institute/ | Mitomycin C, 35 mg/m2 | 90 | No | No | Appendiceal, and |
| Amsterdam (Netherlands) | colorectal carcinomatosis | ||||
| National cancer institute/ | Cisplatin, 43 mg/L | 90 | No | No | Peritoneal mesothelioma, |
| Milan (Italy) | Doxorubicin ,15.25 mg/L | advanced ovarian cancer | |||
| National cancer institute/ | Mitomycin C, 3.3mg/m2/L | 90 | No | No | Appendiceal, and |
| Milan (Italy) | Cisplatin, 25 mg/m2/L | colorectal carcinomatosis; | |||
| advanced ovarian cancer; | |||||
| peritoneal mesothelioma | |||||
| Centre hospitalo-universitaire | Mitomycin C, | 90 | No | No | Appendiceal, gastric and |
| lyon-sud/Lyon (France) | 10 mg/mL of perfusate | colorectal carcinomatosis | |||
| Centre hospitalo-universitaire | Mitomycin C, 0.5 mg/kg | 90 | No | No | Peritoneal mesothelioma |
| lyon-sud/Lyon (France) | Cisplatin 0.7 mg/kg | ||||
| Centre hospitalo-universitaire | Cisplatin, 20 mg/m2/L | 90 | No | No | Recurrent and |
| lyon-sud/Lyon (France) | chemoresistant stage III | ||||
| ovarian cancer | |||||
| National cancer institute/ | Cisplatin, 250 mg/m2 | 90 | No | 5-FU + Taxol | Peritoneal mesothelioma |
| Bethesda, MD (USA) | 1 d |
L: liter of perfusate; HIPEC: Hyperthermic intraperitoneal chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy.